Cabaletta Bio reports rese-cel activity without preconditioning in 4 PV patients; ASGCT presentation May 14

Cabaletta Bio, Inc.

2 of 4 refractory PV patients on rese-cel at lowest dose showed compelling clinical activity through 6 months without preconditioning.
Complete peripheral B-cell elimination observed in 3 of 4 patients; 3 of 4 remained off all immunomodulators and steroids as of April 2, 2026.
Safety: 1 of 4 patients had Grade 1 CRS; no ICANS of any grade. Additional patients enrolled at higher dose in RESET-PV.
RESET-SLE trial initial dose cohort (no preconditioning) fully enrolled; initial data expected first half 2026.
Data to be presented at ASGCT 2026 Annual Meeting on May 14, 2026; higher dose durability data anticipated H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.